Antitrust Antitrust

Teva rejects EU antitrust claims over MS drug, threatens legal fightback

By Nicholas Hirst and Lewis Crofts
  • 10 Oct 2022 10:00
  • 10 Oct 2022 10:16
Teva has said it disputes EU antitrust allegations that it has harmed competition for drugs to manage multiple sclerosis and said it would go to the courts if necessary.
“Today’s statement of objections is a disappointment for Teva as we have been cooperating intensively with the [European Commission] from first

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Nicholas Hirst

Chief Correspondent

Nicholas covers EU merger review and antitrust investigations for Mlex in Brussels. He previously wrote about EU affairs for Politico Europe, European Voice and PaRR. After earning an LLM in European law from the College of Europe in Bruges, he spent a year working in the competition practice of a leading competition law firm in Brussels 2009-10. He graduated in modern European languages from Oxford University in 2006.

Lewis Crofts


Lewis leads MLex's editorial strategy, content direction, quality and development. He has a reputation for breaking stories and providing analysis on complex legal disputes before regulators and courts around the globe. He has also developed MLex's unrivalled coverage of competition policy, litigation, regulation, Brexit and international investigations.

Discover MLex

Stay on top of global regulatory developments

Latest News